Myriad Inks Deal with Pharma Mar to Provide BRCA Testing for Drug Candidate | GenomeWeb

NEW YORK (GenomeWeb News) – Myriad Genetics announced after the close of the market on Thursday an agreement with Pharma Mar to conduct BRCA1 and BRCA2 testing on patients enrolled in a clinical study for the drug firm's novel drug candidate.

Under the agreement, Myriad will conduct testing for patients in a Phase II clinical study for Pharma Mar's PM1183 drug candidate, which induces double-stranded DNA break to cause cell death. Myriad will evaluate BRCA status in patients who respond to the drug candidate.

Financial and other terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: CRISPR-based barcodes to trace cell lineages, and more.

The director of the National Institutes of Health Francis Collins sang the national anthem this week before a baseball game.

French researchers criticize unexpected government plan to cut research funding, ScienceInsider reports.

In Nature this week: genetic mechanism through which some cancers evade the immune system, and more.